UA
EBS icon

Unison Advisors’s Emergent Biosolutions EBS Stock Holding History

Unison Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,957
Closed -$81.5K – 183
2024
Q2 		$81.5K Hold
11,957
– – 0.01% 180
2024
Q1 		$30.3K Hold
11,957
– – ﹤0.01% 179
2023
Q4 		$28.7K Hold
11,957
– – ﹤0.01% 179
2023
Q3 		$40.7K Hold
11,957
– – ﹤0.01% 180
2023
Q2 		$87.9K Hold
11,957
– – 0.01% 178
2023
Q1 		$124K Hold
11,957
– – 0.01% 177
2022
Q4 		$141K Hold
11,957
– – 0.02% 180
2022
Q3 		$251K Buy
11,957
+3,012
+34% +$83.8K 0.05% 172
2022
Q2 		$278K Hold
8,945
– – 0.07% 158
2022
Q1 		$367K Buy
+8,945
New +$395K 0.09% 138

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OHA
Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Unison Advisors's EBS Position: Q3 2024 in Review

Unison Advisors sold out of Emergent Biosolutions (EBS) in Q3 2024, closing a stake of 11,957 shares — an estimated $81.5K sold.

Unison Advisors first reported a position in EBS in Q1 2022 and held it in 10 quarters. The position peaked at $367K in Q1 2022. 140 funds tracked by Wall St. Rank hold EBS as of Q3 2024.

  • Unison Advisors reported no remaining Emergent Biosolutions position as of Q3 2024 after selling out during the quarter.
  • Unison Advisors sold 11,957 Emergent Biosolutions shares in Q3 2024, an estimated $81.5K.
  • Unison Advisors first reported a position in Emergent Biosolutions in Q1 2022 and held it in 10 quarters.
  • Unison Advisors's Emergent Biosolutions position peaked at $367K in Q1 2022.
  • 140 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2024.

Based on Unison Advisors's 13F filing for Q3 2024, filed 9 Oct 2024.